Next-generation Sequencing Market – Global Industry Insights, Trends and Opportunity Analysis, 2016–2024
Additional Information on such Research Findings can be Availed At:
According to an article published in the magazine Scientific American, whole genome testing might not give accurate results all the time. A low risk disease might take a shape and affect the person in his lifetime. However, gene sequencing is helpful in predicting diseases and in most cases, preventing them. In the era of increased health awareness and advanced technologies, people around the world are embracing the early detection techniques so that they can take care of the diseases such as cancer from an early stage. Next generation sequencing is primarily used to predict the diseases which are hereditary in nature.
Next-generation Sequencing Market Taxonomy
On the basis of technology, the global is classified into:
Sequencing By Synthesis (SBS)
Sequencing By Ligation (SBL)
ION Semiconductor Sequencing
Single-Molecule Real-Time Sequencing (SMRT)
Whole Genome Sequencing
De Novo Sequencing
Total RNA and mRNA Sequencing
Targeted RNA Sequencing
Small RNA and Non coding RNA SEQUENCIMG
On the basis of application, the global is classified into:
Agriculture & Animal Research
On the basis of end user, the global is classified into:
Research Centers & Academic/Government Institutes
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
According to global genes, there are 7,000 types of rare diseases in the world and 80% of these diseases are genetic in order. Moreover, as of 2013, 30 million people in the U.S. have rare diseases that accounts for around 10% of the total population of the country. It is estimated that 24 million people in the U.S. suffer from genetic or hereditary diseases. Since next-generation sequencing can be linked to a variety of diseases, its role in treatment is of utmost importance which will fuel the market growth of the market in the region. Moreover, technological advancements as well as development of efficient diagnostic tests will ensure early detection of these diseases, thereby augmenting growth of next-generation sequencing market.
You can also get exclusive discount on this CMI report by clicking on this link: https://www.coherentmarketinsights.com/insight/request-discount/158
Growing prevalence of hereditary diseases and government initiatives will drive the overall next-generation sequencing market
According to a report by Global Genes, in 2009, Europe accounted for around 30 million people of the 350 million people worldwide who suffered from some rare disease. Moreover, children accounted for around half the population affected by rare diseases. According to Net Wellness, more than 20% of the infant deaths are caused due to genetic disorder. These statistics are truly mind boggling and this would increase the demand for gene sequencing techniques thereby augmenting the overall growth of the next-generation sequencing market.
During the estimated period, Asia-Pacific market is likely to grow at the maximum rate owing technological innovation, rising drug discovery programs by healthcare companies, and growing adoption of pioneering treatment models are some of the prime factors that will drive the growth of market in the region. Moreover governments in these region are increasing their overall healthcare spends in their budgets owing to high prevalence of these diseases. This would result in increased initiatives by the healthcare companies and research organizations, in turn fueling growth of the next-generation sequencing market.
Some of the companies operating in the next-generation sequencing market in the current scenario are Life Sciences Corporation (Roche Holding Ag), Agilent Technologies, Life Technologies Corporation, Perkin Elmer, Genomatix Software Gmbh, Illumina, Inc., Genomatix Software Gmbh, Macrogen, Inc., Oxford Nanopore Technologies, Ltd., Gatc Biotech Ag, Dnastar, Inc., IncPartek Incorporated, Knome, Inc., and Qiagen N.V.
Browse Market Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/next-generation-sequencing-market-158
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Next-generation Sequencing Market – Global Industry Insights, Trends and Opportunity Analysis, 2016–2024 here
News-ID: 481088 • Views: 355
More Releases from Next-generation Sequencing Market
Global Next-generation Sequencing Market Trends, Regulations And Competitive Lan …
Albany, NY, 8th March : Recent research and the current scenario as well as future market potential of "Next-generation Sequencing: Emerging Clinical Applications and Global Markets" globally. The global clinical next-generation sequencing (NGS) market reached $2.7 billion in 2016. This market is expected to grow at a compound annual growth rate (CAGR) of 27%, from nearly $3.2 billion in 2017 to $10.5 billion by 2022. Get Free PDF for more Professional and
Global Next-generation Sequencing Market to 2022| Thermo Fisher Scientific, Perk …
Albany, NY, 11th February : Recent research and the current scenario as well as future market potential of "Next-generation Sequencing: Emerging Clinical Applications and Global Markets" globally. Report Includes An overview of the global market for next-generation sequencing and its emerging clinical applications. Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022. Get
Global Next-generation Sequencing Market is expected to grow at a compound annua …
ResearchMoz include new market research report "Next-generation Sequencing: Emerging Clinical Applications and Global Markets" to its huge collection of research reports. The global clinical next-generation sequencing (NGS) market reached $2.7 billion in 2016. This market is expected to grow at a compound annual growth rate (CAGR) of 27%, from nearly $3.2 billion in 2017 to $10.5 billion by 2022. Non-cancer applications as a segment should reach $2.3 billion in 2017 to $6.4
Next-generation Sequencing Market – Global Industry Insights, Trends and Analy …
Growing prevalence of hereditary diseases and government initiatives will drive the overall next-generation sequencing market According to a report by Global Genes, in 2009, Europe accounted for around 30 million people of the 350 million people worldwide who suffered from some rare disease. Moreover, children accounted for around half the population affected by rare diseases. According to Net Wellness, more than 20% of the infant deaths are caused due to genetic
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
DNA/RNA Extraction Equipment Market: Competitive Dynamics & Global Outlook 2023
New report published by Market Research Report Store (MRRS) which offers insights on the global DNA/RNA Extraction Equipment market. Robotic liquid handling technology in automated DNA extraction systems can streamline the tasks involved in extracting DNA from a sample, such as serial dilution and cherry picking. Systems typically also include functions such as shaking, temperature control, and PCR protocols. DNA extraction is used in many types of biological research including molecular
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and